Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Non-Current Assets (2021 - 2025)

Aligos Therapeutics' Non-Current Assets history spans 5 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 28.69% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $26.3 million, down 26.32%, while the annual FY2025 figure was $5.7 million, 28.69% down from the prior year.
  • Non-Current Assets reached $5.7 million in Q4 2025 per ALGS's latest filing, down from $6.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $30.9 million in Q4 2021 to a low of $5.7 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $12.0 million, with a median of $11.5 million recorded in 2023.
  • The largest YoY upside for Non-Current Assets was 4.62% in 2022 against a maximum downside of 57.51% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $30.9 million in 2021, then plummeted by 57.51% to $13.1 million in 2022, then decreased by 20.57% to $10.4 million in 2023, then fell by 23.84% to $8.0 million in 2024, then dropped by 28.69% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Non-Current Assets are $5.7 million (Q4 2025), $6.3 million (Q3 2025), and $6.8 million (Q2 2025).